Zemcelpro® (dorocubicel) positive results in high- and very high-risk blood cancers to be reported
“These findings suggest that Zemcelpro® (dorocubicel) could redefine the standard of care for patients with high- and very high-risk blood cancers,” said David Millette, CEO. “Based on its safety and efficacy profile, this positions Zemcelpro® (dorocubicel) as a potentially transformative therapy, challenging the existing treatment paradigm and offering renewed hope for difficult-to-cure high- and very high-risk patients facing unfavorable outcomes with conventional approaches.”
Share:
More News
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.
“Many solid tumors remain difficult to treat despite advances in immunotherapy,” said Rustam Esanov, CEO and co-founder of Reprogram Biosciences. “Our approach is differentiated by its reprogramming of the tumor itself into a site of immune activation, rather than relying on exogenous immune cells or broadly acting systemic agents.”
Mabwell, an innovation-driven biopharmaceutical company with a fully integrated industry chain, today announced that the first patient has been dosed in a Phase III clinical trial evaluating its novel Nectin-4-targeting ADC (Bulumtatug Fuvedotin, or BFv, R&D code: 9MW2821) for the treatment of locally advanced or metastatic triple-negative breast cancer (TNBC).